245 related articles for article (PubMed ID: 28383421)
1. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.
Han SB; Kim SK; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH
Medicine (Baltimore); 2017 Apr; 96(14):e6546. PubMed ID: 28383421
[TBL] [Abstract][Full Text] [Related]
2. Varicella Zoster Virus Infection in Children with Autologous Hematopoietic Cell Transplantation: A Retrospective, Single-Center Study in Korea.
Kang JM; Kim JM; Lee JW; Yoo KH; Sung KW; Koo HH; Kim YJ
Biol Blood Marrow Transplant; 2020 May; 26(5):965-971. PubMed ID: 31962166
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
[TBL] [Abstract][Full Text] [Related]
4. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Steer CB; Szer J; Sasadeusz J; Matthews JP; Beresford JA; Grigg A
Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
[TBL] [Abstract][Full Text] [Related]
5. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
Onozawa M; Hashino S; Haseyama Y; Hirayama Y; Iizuka S; Ishida T; Kaneda M; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Masauji N; Matsunaga T; Mori A; Mukai M; Nishio M; Noto S; Ota S; Sakai H; Suzuki N; Takahashi T; Tanaka J; Torimoto Y; Yoshida M; Fukuhara T
Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
[TBL] [Abstract][Full Text] [Related]
7. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
9. Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis.
Baumrin E; Cheng MP; Kanjilal S; Ho VT; Issa NC; Baden LR
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1642-1647. PubMed ID: 31004745
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
Kim DH; Kumar D; Messner HA; Minden M; Gupta V; Kuruvilla J; Chae YS; Sohn SK; Lipton JH
Clin Transplant; 2008; 22(6):770-9. PubMed ID: 18707605
[TBL] [Abstract][Full Text] [Related]
11. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Incidence of Varicella Zoster Virus Disease in Adults Receiving Single-Unit Cord Blood Transplantation.
Fukushi K; Konuma T; Monna-Oiwa M; Isobe M; Kato S; Kuroda S; Takahashi S; Nannya Y
Transplant Cell Ther; 2022 Jun; 28(6):339.e1-339.e7. PubMed ID: 35364334
[TBL] [Abstract][Full Text] [Related]
13. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation.
Kawamura K; Hayakawa J; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Hematol; 2015 Aug; 102(2):230-7. PubMed ID: 25990803
[TBL] [Abstract][Full Text] [Related]
14. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of varicella zoster virus infection following allogeneic stem cell transplants].
Doki N; Hoshino T; Irisawa H; Sakura T; Miyawaki S
Rinsho Ketsueki; 2004 Oct; 45(10):1090-4. PubMed ID: 15553042
[TBL] [Abstract][Full Text] [Related]
16. Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children.
Tatebe Y; Ushio S; Esumi S; Sada H; Ochi M; Tamefusa K; Ishida H; Fujiwara K; Kanamitsu K; Washio K; Katsube R; Murakawa K; Zamami Y
Pediatr Blood Cancer; 2022 Dec; 69(12):e29979. PubMed ID: 36151963
[TBL] [Abstract][Full Text] [Related]
17. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
[TBL] [Abstract][Full Text] [Related]
18. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
[TBL] [Abstract][Full Text] [Related]
19. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
Boeckh M; Kim HW; Flowers ME; Meyers JD; Bowden RA
Blood; 2006 Mar; 107(5):1800-5. PubMed ID: 16282339
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
